Skip to main content
SpringerLink
Log in

Liver Cirrhosis

  • Conference proceedings
  • © 2001

Overview

Editors:
  1. Kiwamu Okita

    1. First Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Providing a valuable resource for physicians and hepatologists who are interested not only in fibrogenesis but also in hepatocarcinogenesis

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 papers)

  1. Front Matter

    Pages II-XII
    Download chapter PDF

  2. Mechanisms of Progression and Regression of Liver Fibrosis

    • Michael J. P. Arthur
    Pages 1-9

  3. Analysis of Proteins and Genes Dominantly Expressed in Stellate Cells of Activated Phenotype: the Molecular Approach to Liver Fibrosis

    • Norifumi Kawada
    Pages 10-16

  4. Novel Therapeutic Modalities for Hepatic Diseases

    • Henning Wege, Jian Wu, Mark A. Zern
    Pages 17-29

  5. Gene Therapy for Liver Cirrhosis: Novel Treatment in the New Millennium

    • Jiro Fujimoto, Takahiro Ueki
    Pages 30-35

  6. Present Status and Future of Gene Therapy for Hepatic Fibrosis

    • Takato Ueno, Toru Nakamura, Hikaru Ueno, Kyuichi Tanikawa, Michio Sata
    Pages 36-43

  7. Inhibitory Effects of the Herbal Medicine Sho-saiko-to on Liver Fibrosis

    • Kozo Kayano, Isao Sakaida, Kiwamu Okita
    Pages 44-55

  8. Resolution of Fibrosis in Hepatitis C Patients with Sustained Response to Interferon: Long-Term Effects of Interferon Therapy on Histological Improvement

    • Yasushi Shiratori, Haruhiko Yoshida, Masao Omata
    Pages 56-64

  9. Factors Related to the Development of Hepatocellular Carcinoma from Chronic Liver Diseases Type B and C

    • Takeshi Okanoue, Yoshiki Murakami, Masahito Minami, Yoshito Itoh
    Pages 65-72

  10. Quasispecies of Hepatitis C Virus in Serum and in Three Different Parts of the Liver of Patients with Chronic Hepatitis

    • Masao Honda, Akito Sakai, Shuichi Kaneko, Kenichi Kobayashi
    Pages 73-79

  11. Development of Hepatocellular Carcinoma in Liver Cirrhosis: Pathomorphologic Viewpoint

    • Masamichi Kojiro
    Pages 80-86

  12. HGF-Related Proteins in Hepatocellular Carcinoma (HCC)

    • Shuichi Hirono, Kenji Nagata, Akihiro Ivioriuchi, Masaaki Onaga, Himiko Fujiwara, Takeshi Hori et al.
    Pages 87-92

  13. Significance of α1-6 Fucosylation in Hepatocellular Carcinoma

    • Eiji Miyoshi, Katsuhisa Noda, Naoyuki Taniguchi, Yutaka Sasaki, Norio Hayashi
    Pages 93-104

  14. Energy Metabolism in Liver Cirrhosis: Its Characteristics, Clinical Significance, and Possible Intervention

    • Hisataka Moriwaki, Masahiro Tajika, Yoshiyuki Miwa, Masahiko Kato
    Pages 105-111

  15. Effects of Abnormal Hormone Dynamics on Protein-Energy Malnutrition in Cirrhotic Patients: Pathophysiological and Therapeutic Implications

    • Akiharu Watanabe
    Pages 112-122

  16. Back Matter

    Pages 123-125
    Download chapter PDF
Back to top

Keywords

About this book

Since 1998, the Japanese Society of Hepatology has campaigned to fight hepatocellu­ lar carcinoma (HCC). Because the mortality rate for this disease has reached more than 30 per 100,000 population, the organizing committee chose HCC as the main topic of the 1999 Yamaguchi Symposium on Liver Diseases. Regarding hepatocar­ cinogenesis, we know that HCC often develops secondary to liver cirrhosis; thus liver cirrhosis must be recognized as a prevalent pathological condition leading to HCC. If we can control liver fibrosis, we can reduce the risk for HCC among patients with chronic hepatitis. To achieve this goal, we must know more about hepatic fibrosis. Professor Michael J. P. Arthur is familiar as a leading scientist in this field. We were fortunate that he accepted our invitation to speak. His lecture titled "Mechanisms of the Progression and Regression of Liver Fibrosis" provided important advice for developing antifibrotic agents. We also invited Professor Mark A. Zern, who has been studying hepatic fibrosis for some time. In the symposium he talked about novel approaches, including gene therapy, to treat acute and chronic hepatic diseases in the 21st century. In addition to the informative talks by those guests from abroad, the lecture by Dr. J. Fujimoto was very impressive. He revealed that gene therapy using hepatocyte growth factor (HGF) could inhibit progression to liver cirrhosis in rats repeatedly injected with dimethylnitrosamine (DMN). Dr. Fujimoto has already pub­ lished his finding that administration of HGF reduced hepatocarcinogenesis in rats.

Editors and Affiliations

  • First Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan

    Kiwamu Okita

Bibliographic Information

  • Book Title: Liver Cirrhosis

  • Editors: Kiwamu Okita

  • DOI: https://doi.org/10.1007/978-4-431-68343-8

  • Publisher: Springer Tokyo

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Japan 2001

  • Hardcover ISBN: 978-4-431-70294-8Published: 01 December 2000

  • Softcover ISBN: 978-4-431-68345-2Published: 22 January 2013

  • eBook ISBN: 978-4-431-68343-8Published: 14 March 2013

  • Edition Number: 1

  • Number of Pages: XII, 125

  • Topics: Hepatology

Publish with us

Policies and ethics

Back to top

Search

Navigation